drugset
drugset / Trial / NCT03758664

Clinical Study of ICP-192 in Solid Tumors Patients

NCT03758664 ↗

Phase 1/2 Unknown 56 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

Timeline

Start
2018-12-19
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ICP-192 Unknown 2 mg —

Indications

cancer